WHAT IS CLAIMED IS:

1. Antitumor and antiviral medications produced by activating lymphocytes and inducing heat shock proteins in said activated lymphocytes.

2. The antitumor and antiviral medications set forth in claim 1, wherein said induced heat shock proteins has a molecular weight of 60 kDa to 80 kDa.

3. The antitumor and antiviral medications set forth in claim 1, wherein said induced heat shock proteins has a molecular weight of 70 kDa.

4. The antitumor and antiviral medications set forth in claim 1, wherein said heat shock proteins are induced by heating said activated lymphocytes.

5. The antitumor and antiviral medications set forth in claim 2, wherein said heat shock proteins are induced by heating said activated lymphocytes.

6. The antitumor and antiviral medications set forth in claim 3, wherein said heat shock proteins are induced by heating said activated lymphocytes.

7. The antitumor and antiviral medications set forth in claim 4, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃, thereby to induce said heat shock proteins.

8. The antitumor and antiviral medications set forth in claim 5, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃, thereby to induce said heat shock proteins.

9. The antitumor and antiviral medications set forth in claim 6, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃, thereby to induce said heat shock proteins.

10. The antitumor and antiviral medications set forth in claim 4, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃ for 5 seconds to 6 hours, thereby to induce said heat shock proteins.

11. The antitumor and antiviral medications set forth in claim 5, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃ for 5 seconds to 6 hours, thereby to induce said heat shock proteins.

12. The antitumor and antiviral medications set forth in claim 6, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃ for 5 seconds to 6 hours, thereby to induce said heat shock proteins.

13. The antitumor and antiviral medications set forth in claim 4, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃, thereby to induce said heat shock proteins.

14. The antitumor and antiviral medications set forth in claim 5, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃, thereby to induce said heat shock proteins.

15. The antitumor and antiviral medications set forth in claim 6, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃, thereby to induce said heat shock proteins.

16. The antitumor and antiviral medications set forth in claim 4, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃ for 10 minutes to 60 minutes, thereby to induce said heat shock proteins.

17. The antitumor and antiviral medications set forth in claim 5, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃ for 10 minutes to 60 minutes, thereby to induce said heat shock proteins.

18. The antitumor and antiviral medications set forth in claim 6, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃ for 10 minutes to 60 minutes, thereby to induce said heat shock proteins.

19. The antitumor and antiviral medications set forth in claim 4, wherein said heat shock proteins are induced by adding galenical extract of crude drug or its compounds to a culture solution of said activated lymphocytes.

20. The antitumor and antiviral medications set forth in claim 5, wherein said heat shock proteins are induced by adding galenical extract of crude drug or its compounds to a culture solution of said activated lymphocytes.

21. The antitumor and antiviral medications set forth in claim 6, wherein said heat shock proteins are induced by adding galenical extract of crude drug or its compounds to a culture solution of said activated lymphocytes.

22. The antitumor and antiviral medications set forth in claim 19, wherein said crude drug is Rauwolfia serpentina.

23. The antitumor and antiviral medications set forth in claim 20, wherein said crude drug is Rauwolfia serpentina.

24. The antitumor and antiviral medications set forth in claim 21, wherein said crude drug is Rauwolfia serpentina.

25. The antitumor and antiviral medications set forth in claim 22, wherein the compound of said Rauwolfia serpentina is reserpine.

26. The antitumor and antiviral medications set forth in claim 23, wherein the compound of said Rauwolfia serpentina is reserpine.

27. The antitumor and antiviral medications set forth in claim 24, wherein the compound of said Rauwolfia serpentina is reserpine.

28. The antitumor and antiviral medications set forth in claim 19, wherein said crude drug is linderae radix.

29. The antitumor and antiviral medications set forth in claim 20, wherein said crude drug is linderae radix.

30. The antitumor and antiviral medications set forth in claim 21, wherein said crude drug is linderae radix.

31. The antitumor and antiviral medications set forth in claim 19, wherein said crude drug is safflower extract.

32. The antitumor and antiviral medications set forth in claim 20, wherein said crude drug is safflower extract.

33. The antitumor and antiviral medications set forth in claim 21, wherein said crude drug is safflower extract.

34. The antitumor and antiviral medications set forth in claim 19, wherein said crude drug is Scutellariae Radix.

35. The antitumor and antiviral medications set forth in claim 20, wherein said crude drug is Scutellariae Radix.

36. The antitumor and antiviral medications set forth in claim 21, wherein said crude drug is Scutellariae Radix.

37. Antitumor medications consisting of reserpine alone or containing reserpine as a chief ingredient.

38. The antitumor and antiviral medications set forth in claim 37, wherein said reserpine is derived from galenical extract from Rauwolfia serpentina.

39. A method for producing antitumor and antiviral medications comprising the steps of activating lymphocytes, and heating said lymphocytes activated, thereby to induce heat shock proteins in said lymphocytes.

40. The method for producing antitumor and antiviral medications set forth in claim 39, wherein said induced heat shock proteins has a molecular weight of 60 kDa to 80 kDa.

41. The method for producing antitumor and antiviral medications set forth in claim 39, wherein said induced heat shock proteins has a molecular weight of 70 kDa.

42. The method for producing antitumor and antiviral medications set forth in claim 39, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃, thereby to induce said heat shock proteins.

43. The method for producing antitumor and antiviral medications set forth in claim 40, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃, thereby to induce said heat shock proteins.

44. The method for producing antitumor and antiviral medications set forth in claim 41, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃, thereby to induce said heat shock proteins.

45. The method for producing antitumor and antiviral medications set forth in claim 39, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃ for 5 seconds to 6 hours, thereby to induce said heat shock proteins.

46. The method for producing antitumor and antiviral medications set forth in claim 40, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃ for 5 seconds to 6 hours, thereby to induce said heat shock proteins.

47. The method for producing antitumor and antiviral medications set forth in claim 41, wherein said lymphocytes are heated at temperatures of 38℃ to 50℃ for 5 seconds to 6 hours, thereby to induce said heat shock proteins.

48. The method for producing antitumor and antiviral medications set forth in claim 39, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃ for 10 minutes to 60 minutes, thereby to induce said heat shock proteins.

49. The method for producing antitumor and antiviral medications set forth in claim 40, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃ for 10 minutes to 60 minutes, thereby to induce said heat shock proteins.

50. The method for producing antitumor and antiviral medications set forth in claim 41, wherein said lymphocytes are heated at temperatures of 42℃ to 45℃ for 10 minutes to 60 minutes, thereby to induce said heat shock proteins.

51. A method for producing antitumor and antiviral medications comprising the steps of activating lymphocytes, and adding galenical extract of crude drug or its compounds to a culture solution of said activated lymphocytes, thereby to induce heat shock proteins in said lymphocytes.

52. The method for producing antitumor and antiviral medications set forth in claim 51, wherein said crude drug is Rauwolfia serpentina, linderae radix extract, safflower extract or Scutellariae Radix.

53. A method for producing antitumor and antiviral medications comprising the steps of activating lymphocytes, and concurrently heating said activated lymphocytes and adding galenical extract of crude drug or its compounds to a culture solution of said activated lymphocytes, thereby to induce heat shock proteins having a molecular weight of 60 kDa to 80 kDa in said lymphocytes.

54. A method for producing antitumor and antiviral medications comprising the steps of activating lymphocytes, heating said activated lymphocytes, and concurrently administering, to a living body, said activated lymphocytes thus heated and galenical extract of crude drug or its compounds, thereby to induce heat shock proteins having a molecular weight of 60 kDa to 80 kDa in said lymphocytes.